- Home
- KYNB vs LSTA Comparison
KYNB vs LSTA Comparison
Compare KYNB & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KYNB | LSTA |
|---|---|---|
| Founded | 1993 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 28.9M |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | KYNB | LSTA |
|---|---|---|
| Price | $6.91 | $3.21 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 6.5K | ★ 95.3K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 20.42 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.15 | ★ N/A |
| Revenue Growth | N/A | ★ 56.90 |
| 52 Week Low | $6.32 | $1.81 |
| 52 Week High | $9.58 | $5.07 |
Technical Indicators
Market Signals| Indicator | KYNB | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 37.04 |
| Support Level | $6.67 | $1.82 |
| Resistance Level | $7.42 | $3.43 |
| Average True Range (ATR) | 0.17 | 0.14 |
| MACD | -0.02 | 0.04 |
| Stochastic Oscillator | 11.72 | 52.63 |
Price Performance
Historical ComparisonAbout KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.